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Correction: Marked variability in bioactivity
between commercially available bovine
colostrum for human use; implications for
clinical trials
Raymond J. Playford, Meg Cattell, Tania Marchbank
In Table 1, there are errors in the titles of the products tested under “COLOSTRUM”, the val-
ues under “Total stated protein (g/100 g)” and “Total IgG (g/100g)”, and the “Lot number” val-
ues. Please see the correct Table 1 here.
Table shows source of colostrum samples and product data sheet information for total pro-
tein, total IgG, lot numbers and recommended storage conditions, NS = not stated. RT =
(store at) room temperature. Storage advice was either present on data sheet or through direct
contact with producer. NB list of products are described in random order and do not relate to
the order of bioactivity.
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Table 1. Commercial colostrum sample information provided by producer.
COLOSTRUM Total stated protein
(g/100g)
Form Source Total IgG
(g/100g)
Recommended storage Lot number
Neovite lactose reduced first milk 70 Powder UK 28 Cool dry place 1805082
Neovite whole colostrum from Welsh farms 55 Powder UK 16.5 Cool dry place SA44-01
Neovite cow’s first milk 55 Powder UK 16.5 Cool dry place 1801007
ColoDan whole colostrum NS Powder Denmark 13 Cool dry place
B5032-017
Bulkpowders colostrum 63.3 Powder Germany 30 Cool dry place NS
Biestmilch 70 Capsule Hawaii NS Store for up to 3 year at RT 171241
Vitacost colostrum ultra NS Capsule USA 40 Room Temp 15–30 0C 3823400
Douglas Laboratories colostrum NS Powder New Zealand NS Cool dry place 15–25 0C 50153284
Immune Tree colostrum 66.7 Powder USA NS Cool dry place 9902/143
Nutricost NS Capsule USA NS NS (shipped at RT) 18010466
NOW colostrum powder NS Powder USA NS Cool dry place 3046338
Nutrablast NS Capsule USA 7 Cool dry place 279331
Sovereign Laboratories Colostrum-LD 60 Powder USA 25 Cool dry place 1802027
Synertek Intact Balanced First colostrum 66.7 Powder USA NS Cool dry place <25 0C 657–30
Renegade Pharmacist 66.7 Powder USA 22.11 NS (shipped at RT) 9902/221
Sterling Technology colostrum 2070 70 Powder USA 20 NS (shipped at RT) 0237418
TBR labs peptide ignition colostrum 66.7 Powder USA >20 Cool dry place 03028219
Sterling Technology colostrum 3070 70 Powder USA 30 NS (shipped at RT) 2396–9
Glanbia high fat WPC 88 Powder USA NS NS (shipped at RT) 0068701
Pantheryx Standard colostrum 4515 45 Powder USA 15 Store at RT for up to 3 years 1141–048203 4518Fi
https://doi.org/10.1371/journal.pone.0240392.t001
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Some of the symbols in the caption for Fig 4 are incorrect. Please see the complete, correct
Fig 4 caption here. The publisher apologizes for the errors.
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Fig 4. Change in colostral biological and immunoactivity post calving using AGS cells. Colostrum was collected at first and second milking and daily for the
following 3 days from 6 cows post calving. Samples were then analysed for pro-proliferative activity (AGS cells) using Alamar Blue and growth factor concentrations
using commercial ELISA kits. A. Proliferative results comparing samples using 1 mg powder/ml. B. Proliferative results comparing samples standardised so that each
well received 0.4 mg protein/ml. Results expressed as % response compared to effect caused by adding 1μg/ml EGF (positive control, defined as 100%). SFM shows result
of serum free medium alone. Results expressed as mean +/- SEM of 6 animals per time point, with each sample measured in quadruplicate. C. Change in total protein
concentration in the dried colostrum samples over the four-day period. D. Growth factor immunoreactivity expressed as % of Day 0–1 sample (absolute values of day
0–1 given in main text); EGF (▲), TGFβ (▼), bovine haptoglobin (●), bovine betacellulin (■), IGF-1 (□) and IgG (�). Results expressed as mean +/- SEM of 6 animals per
time point, with each sample measured in triplicate. For A-D, �� signifies p<0.01 vs Day 0–1 value.
https://doi.org/10.1371/journal.pone.0240392.g001
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